Log In
BCIQ
Print this Print this
 

AR08

  Manage Alerts
Collapse Summary General Information
Company Arbor Pharmaceuticals Inc.
Description 
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat attention deficit hyperactivity disorder (ADHD) in children ages 6 to 17
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today